CA2605574A1 - Methods, compositions and compound assays for inhibiting amyloid-beta protein production - Google Patents

Methods, compositions and compound assays for inhibiting amyloid-beta protein production Download PDF

Info

Publication number
CA2605574A1
CA2605574A1 CA002605574A CA2605574A CA2605574A1 CA 2605574 A1 CA2605574 A1 CA 2605574A1 CA 002605574 A CA002605574 A CA 002605574A CA 2605574 A CA2605574 A CA 2605574A CA 2605574 A1 CA2605574 A1 CA 2605574A1
Authority
CA
Canada
Prior art keywords
dna
gpr3
amyloid
gpr12
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002605574A
Other languages
English (en)
French (fr)
Inventor
Pascal Gerard Merchiers
Koenraad Frederik Florentina Spittaels
Marcel Hoffmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2605574A1 publication Critical patent/CA2605574A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002605574A 2004-04-20 2005-04-20 Methods, compositions and compound assays for inhibiting amyloid-beta protein production Abandoned CA2605574A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56366104P 2004-04-20 2004-04-20
US60/563,661 2004-04-20
PCT/EP2005/004325 WO2005103713A2 (en) 2004-04-20 2005-04-20 Methods, compositions and compound assays for inhibiting amyloid-beta protein production

Publications (1)

Publication Number Publication Date
CA2605574A1 true CA2605574A1 (en) 2005-11-03

Family

ID=35197590

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002605574A Abandoned CA2605574A1 (en) 2004-04-20 2005-04-20 Methods, compositions and compound assays for inhibiting amyloid-beta protein production

Country Status (10)

Country Link
US (3) US7429459B2 (enExample)
EP (3) EP2267458A3 (enExample)
JP (1) JP4890442B2 (enExample)
AT (1) ATE483981T1 (enExample)
CA (1) CA2605574A1 (enExample)
DE (1) DE602005023976D1 (enExample)
DK (1) DK1745295T3 (enExample)
ES (1) ES2353604T3 (enExample)
SI (1) SI1745295T1 (enExample)
WO (1) WO2005103713A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1745295T3 (da) * 2004-04-20 2011-01-31 Galapagos Nv Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein
NZ575804A (en) * 2006-09-13 2012-01-12 Univ Columbia Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass
GB0700645D0 (en) * 2007-01-12 2007-02-21 Eisai London Res Lab Ltd Targets for disease therapy
US7968524B2 (en) * 2007-05-15 2011-06-28 Helicon Therapeutics, Inc. Methods of enhancing long term memory formation by inhibition of Gpr12
AU2008254907A1 (en) * 2007-05-15 2008-11-27 Helicon Therapeutics, Inc. Methods of identifying genes involved in memory formation using small interfering RNA(siRNA)
JP5049713B2 (ja) * 2007-09-14 2012-10-17 株式会社コナミデジタルエンタテインメント ゲームシステム並びにこれを構成するゲーム装置及び課題報知装置
EP2440934B1 (en) * 2009-06-08 2014-07-16 Vib Vzw Screening for compounds that modulate gpr3-mediated beta-arrestin signaling and amyloid beta peptide generation
WO2011102901A1 (en) * 2010-02-20 2011-08-25 Ebiotec (Euroespes Biotechnology) Prevention and treatment of alzheimer's disease by amyloid beta peptide and sphingosine-1-phosphate
US20130331330A1 (en) * 2012-06-08 2013-12-12 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating alzheimer's disease and other tauopathies with inhibitors of microtubule affinity regulating kinase
US20150065376A1 (en) * 2013-08-12 2015-03-05 Holger Knaut Expression constructs encoding g protein coupled receptors and methods of use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
JPH07509133A (ja) 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5998164A (en) 1995-03-30 1999-12-07 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein coupled receptor GPRZ
US6090575A (en) 1995-03-30 2000-07-18 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein coupled receptor GPR1
AU2236895A (en) 1995-03-30 1996-10-16 Human Genome Sciences, Inc. Human g-protein coupled receptors
US6653086B1 (en) * 1998-04-14 2003-11-25 Arena Pharmaceuticals, Inc. Endogenous constitutively activated G protein-coupled orphan receptors
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US6420563B1 (en) 1998-07-31 2002-07-16 Arena Pharmaceuticals, Inc. Small molecule modulators of G protein-coupled receptor six
CN1364167A (zh) 1999-02-26 2002-08-14 阿瑞那制药公司 G蛋白偶联受体6的小分子调节剂
JP2003518628A (ja) * 1999-12-10 2003-06-10 アストラゼネカ アクチボラグ 化合物
WO2001084158A1 (en) * 2000-05-03 2001-11-08 Astrazeneca Ab Use of the g protein coupled receptor gpr3 to identify appetite control agents
WO2001090128A2 (en) * 2000-05-24 2001-11-29 Genaissance Pharmaceuticals, Inc. Haplotypes of the gpr3 gene
US7163800B2 (en) 2000-11-03 2007-01-16 Molecular Devices Corporation Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
US20050118639A1 (en) * 2002-02-22 2005-06-02 Takeda Chemical Industries, Ltd Method of determining ligand
WO2003097795A2 (en) * 2002-05-13 2003-11-27 Norak Biosciences, Inc. Constitutively translocating cell line
JP4184875B2 (ja) * 2002-06-14 2008-11-19 武田薬品工業株式会社 新規スクリーニング方法
US20040023384A1 (en) * 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of G protein-coupled receptor 12 expression
US20040023380A1 (en) * 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of G protein-coupled receptor 6 expression
WO2004038407A2 (en) * 2002-10-24 2004-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
AU2003301892A1 (en) 2002-11-04 2004-06-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3)
AU2003224132A1 (en) 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
EP1662862A1 (en) * 2003-09-19 2006-06-07 Paradigm Therapeutics Limited Receptor
DK1745295T3 (da) * 2004-04-20 2011-01-31 Galapagos Nv Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein

Also Published As

Publication number Publication date
EP2270513A2 (en) 2011-01-05
DK1745295T3 (da) 2011-01-31
EP1745295B1 (en) 2010-10-06
WO2005103713A2 (en) 2005-11-03
JP4890442B2 (ja) 2012-03-07
JP2007533989A (ja) 2007-11-22
EP2267458A3 (en) 2011-04-06
ATE483981T1 (de) 2010-10-15
DE602005023976D1 (de) 2010-11-18
EP1745295A2 (en) 2007-01-24
EP2270513A3 (en) 2011-04-06
US7429459B2 (en) 2008-09-30
US20110118338A1 (en) 2011-05-19
SI1745295T1 (sl) 2011-01-31
US7910320B2 (en) 2011-03-22
US20090005262A1 (en) 2009-01-01
WO2005103713A3 (en) 2006-09-08
US20050266502A1 (en) 2005-12-01
ES2353604T3 (es) 2011-03-03
HK1099810A1 (en) 2007-08-24
EP2267458A2 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
US7910320B2 (en) Methods compositions and compound assays for inhibiting amyloid-beta protein production
US20050287565A1 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
US7919259B2 (en) Methods for identification, and compounds useful for the treatment of degenerative and inflammatory diseases
WO2008008463A2 (en) METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING SAPPβ
CA2562833A1 (en) Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
WO2005119262A2 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2005024058A2 (en) Compounds for the treatment of diseases involving cognitive impairment, such as alzheimer’s disease, and methods for identifying such compounds
US20140256790A1 (en) Methods for Identifying and Compounds Useful for Increasing the Functional Activity and Cell Surface Expression of CF-Associated Mutant Cystic Fibrosis Transmembrance Conductance Regulator
US20070004624A1 (en) Methods for modulating bone tissue formation, orthogenic agents and pharmaceutical compositions
WO2005103693A2 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
HK1099810B (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
US20050277612A1 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2005103715A2 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2005103689A1 (en) Novel compounds for the treatment of alzheimer’s disease and methods for identifying same
WO2005103707A1 (en) Novel compounds for the treatment of alzheimer’s disease and methods for identifying same
EP2440934B1 (en) Screening for compounds that modulate gpr3-mediated beta-arrestin signaling and amyloid beta peptide generation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130422